Major Institutional Moves in Bristol-Myers Squibb Holdings

2 min read | November 11, 2024 09:55 PM PST | By Team Kalkine Media

Headlines

  • Mesirow Financial Adjusts Holdings in Bristol-Myers Squibb
  • Institutional Investors Increase Positions in Bristol-Myers Squibb
  • Growing Stake Among Hedge Funds and Financial Firms

Mesirow Financial Investment Management Inc. recently adjusted its holdings in Bristol-Myers Squibb (NYSE:BMY), reducing its position by a substantial margin during the third quarter. As of the end of this reporting period, Mesirow held shares worth over a million dollars. This adjustment is part of a broader trend where institutional investors are actively managing their shares in the biopharmaceutical leader, Bristol-Myers Squibb.

Numerous hedge funds and investment firms have also modified their positions in Bristol-Myers Squibb. Capital International Investors recently increased its holdings, reflecting strong interest and confidence from financial institutions. Primecap Management Co. CA also made a minor addition to its portfolio, signaling continuous engagement with the company.

Further emphasizing institutional interest, Legal & General Group Plc, a significant institutional player, has raised its stake in the biopharma firm, indicating sustained investment support. Similarly, Independent Franchise Partners LLP boosted its position, contributing to the overall rise in institutional ownership of Bristol-Myers Squibb shares. This trend illustrates the company's prominence among large financial organizations and highlights the strategic adjustments made by key stakeholders.

Pzena Investment Management LLC also expanded its shares in Bristol-Myers Squibb, reflecting the continued attraction of this healthcare giant within the investment community. Overall, these updates showcase how institutional investors are positioning themselves in Bristol-Myers Squibb, with major players aligning to maintain a significant presence.

Bristol-Myers Squibb remains a focal point for diverse financial entities, with institutional investors holding a considerable portion of its shares. This activity underscores the interest and strategic involvement from key financial firms, suggesting strong engagement with the company’s ongoing developments in the biopharmaceutical field.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.


Sponsored Articles


Investing Ideas

Previous Next